What Is Bilirubin and Where Does It Come From?
Bilirubin is a yellow-orange pigment — the breakdown product of haem, the iron-containing component of haemoglobin in red blood cells. When red blood cells reach the end of their roughly 120-day lifespan, they are dismantled in the spleen and liver. The haemoglobin is stripped of its haem group, which is converted first to biliverdin and then to bilirubin.
This freshly produced bilirubin — called indirect (unconjugated) bilirubin — is fat-soluble, binds to albumin in the bloodstream, and travels to the liver. There, liver cells (hepatocytes) attach glucuronic acid molecules to it in a process called conjugation, converting it to direct (conjugated) bilirubin — now water-soluble. The liver secretes conjugated bilirubin into bile, which flows through the bile ducts into the small intestine, where gut bacteria convert it to urobilinogen and then stercobilin — the pigment that gives stools their brown colour.
When any step in this chain is disrupted — too many red cells breaking down, the liver failing to conjugate, or bile ducts blocked — bilirubin accumulates in the blood. Above roughly 2–3 mg/dL, it deposits in skin and the whites of the eyes, causing the yellow discoloration known as jaundice (icterus).
Why two fractions matter: The split between direct and indirect bilirubin is the single most useful clue to where the problem lies. Pre-hepatic causes (haemolysis, Gilbert syndrome) raise indirect bilirubin. Hepatic and post-hepatic causes (liver disease, bile duct obstruction) raise direct bilirubin. Total bilirubin alone cannot tell you this.
Normal Ranges and Units
Bilirubin is reported in either milligrams per decilitre (mg/dL) — standard in the US and South Asia — or micromoles per litre (µmol/L), used in most of Europe, Australia, and the UK. To convert: divide µmol/L by 17.1 to get mg/dL.
| Fraction | Normal (mg/dL) | Normal (µmol/L) | Clinical note |
|---|---|---|---|
| Total bilirubin | 0.1–1.2 | 1.7–20.5 | Sum of direct + indirect |
| Direct (conjugated) | 0–0.3 | 0–5.1 | Elevated = hepatic or biliary cause |
| Indirect (unconjugated) | 0.1–0.9 | 1.7–15.4 | Elevated = haemolysis or Gilbert |
Values vary slightly between laboratories. Most labs flag total bilirubin above 1.2 mg/dL, but mild elevations up to 1.5 mg/dL are common in Gilbert syndrome and are not clinically significant in isolation. Always review the fraction split before interpreting a mildly elevated total.
Causes of Elevated Bilirubin by Fraction
Distinguishing which fraction is elevated immediately narrows the differential diagnosis significantly:
Elevated Indirect (Unconjugated) Bilirubin
| Cause | Mechanism | Key Distinguishing Features |
|---|---|---|
| Gilbert syndrome | Reduced UGT1A1 enzyme activity — impaired conjugation | Benign; mild (1–3 mg/dL); worsens with fasting/illness; LFTs otherwise normal |
| Haemolytic anaemia | Excess red cell breakdown overwhelms conjugation capacity | Low haemoglobin, raised LDH and reticulocytes, low haptoglobin |
| Ineffective erythropoiesis | Destruction of immature red cells in bone marrow | Seen in thalassaemia, sideroblastic anaemia, B12/folate deficiency |
| Crigler-Najjar syndrome | Severe/absent UGT1A1 — rare genetic disorder | Presents in neonates; type I is life-threatening without phototherapy |
Elevated Direct (Conjugated) Bilirubin
| Cause | Mechanism | Key Features |
|---|---|---|
| Viral hepatitis (A, B, C, E) | Hepatocyte injury impairs conjugation and secretion | Markedly elevated ALT/AST; positive viral serology |
| Alcoholic hepatitis | Hepatocyte injury + cholestasis | AST:ALT ratio > 2; GGT elevated; alcohol history |
| MASLD / NASH | Mild hepatocyte dysfunction in advanced disease | Usually mild; significant rise suggests cirrhosis or decompensation |
| Cirrhosis | Reduced functional hepatocyte mass impairs all bilirubin processing | Component of MELD, Child-Pugh; rising bilirubin = decompensation signal |
| Bile duct obstruction | Blocked outflow causes conjugated bilirubin back-flux | Elevated ALP and GGT; dark urine, pale stools; visible on imaging |
| Primary biliary cholangitis (PBC) | Autoimmune destruction of small bile ducts | Elevated ALP; AMA antibody positive; usually middle-aged women |
| Drug-induced liver injury (DILI) | Hepatotoxic or cholestatic pattern depending on drug | Temporal link to medication; variable enzyme pattern |
Bilirubin and Jaundice: What the Levels Mean Clinically
Jaundice is not a diagnosis — it is a sign. Visible yellowing of the sclerae (whites of the eyes) and skin occurs when total bilirubin exceeds approximately 2–3 mg/dL. The degree of elevation provides useful clinical context:
| Total Bilirubin Level | Clinical Interpretation | Typical Context |
|---|---|---|
| < 1.2 mg/dL | Normal | No concern |
| 1.2–2.5 mg/dL | Mildly elevated — no visible jaundice | Gilbert syndrome, early liver disease, haemolysis |
| 2.5–5.0 mg/dL | Visible jaundice likely | Acute hepatitis, biliary obstruction, decompensating cirrhosis |
| 5–10 mg/dL | Significant jaundice | Moderate–severe hepatitis, biliary obstruction, acute liver injury |
| > 10 mg/dL | Severe — urgent evaluation needed | Severe hepatitis, acute liver failure, complete biliary obstruction, decompensated cirrhosis |
In patients with established liver disease, rising bilirubin is one of the most important indicators of disease progression. It is a core component of the MELD score (along with creatinine and INR) and the Child-Pugh score — both used to assess prognosis and transplant priority in cirrhosis. A bilirubin above 3 mg/dL is a criterion for Child-Pugh class C (most advanced), and in acute alcoholic hepatitis, a bilirubin above 5 mg/dL combined with a discriminant function score drives decisions about corticosteroid therapy.
Seek urgent medical attention if you develop visible jaundice alongside: fever, severe abdominal pain, confusion or altered mental state, very dark urine and pale stools, significant weight loss, or known liver disease with new jaundice. These combinations can indicate acute liver failure, biliary sepsis (cholangitis), or decompensation of cirrhosis — all requiring prompt assessment.
Bilirubin in Specific Liver Conditions
Bilirubin in MASLD (Fatty Liver Disease)
In early and moderate MASLD, bilirubin is typically normal or only mildly elevated. Because Gilbert syndrome affects roughly 5–10% of the population, many MASLD patients who present with slightly elevated bilirubin actually have the two conditions coincidentally. A significant or rising bilirubin in a known MASLD patient should not be attributed to steatosis alone — it warrants assessment for fibrosis progression, decompensation, or a separate biliary problem.
Bilirubin as a Prognostic Marker in Cirrhosis
As cirrhosis advances, the liver progressively loses the hepatocyte mass needed to conjugate and excrete bilirubin effectively. In compensated cirrhosis, bilirubin may remain normal or only mildly elevated. The transition to decompensated cirrhosis — marked by ascites, variceal bleeding, encephalopathy, or jaundice — is often heralded by a rising bilirubin. In MELD 3.0 (the current transplant allocation score), bilirubin contributes logarithmically: small increases at high levels have major prognostic weight.
Conjugated Hyperbilirubinaemia and Dark Urine
When direct (conjugated) bilirubin is elevated, the water-soluble form spills into urine, turning it dark brown or tea-coloured — a characteristic finding in hepatitis and biliary obstruction. Simultaneously, less bilirubin reaches the gut, producing pale or clay-coloured stools. This combination of dark urine and pale stools is a classic sign of obstructive jaundice and always warrants urgent investigation with liver ultrasound and hepatology review.